Behind the deal: How MD Anderson's partnership with Sophia Genetics advances cancer diagnosis

Next-generation cancer tests are being developed here in Houston, and the HBJ pulled back the curtain on how one partnership ...

Austin FC owners Tench, Simone Coxe give $100M for two new UT hospitals

Austin FC owners Simone, Tench Coxe are providing seed money to encourage others to donate to $2.5 billion project for a ...

RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics Leading candidate ...

Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances

Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode. Oncolytics Biotech ...

Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic

Detailed price information for Radiopharm Theranostics Limited ADR (RADX-Q) from The Globe and Mail including charting and trades.

Radiopharm Theranostics: RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received ...
American Association of Individual Investors

Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 18.13%

As of Friday, January 09, Allogene Therapeutics, Inc.’s ALLO share price has surged by 18.13%, which has investors ...

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center , positioning the company for ...
American Association of Individual Investors

Why Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Down 5.01%

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
The Cool Down on MSN

Parents sound alarm over uptick in devices with disturbing features marketed toward children: 'Looks like a toy and rewards you for using it'

"When a vape looks like a toy and rewards you for using it, it is not just a product — it is a behavioral trap," Unger warned ...